Overview

A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®

Status:
Completed
Trial end date:
2018-06-19
Target enrollment:
0
Participant gender:
Female
Summary
AME is a non-interventional, prospective, longitudinal and multicenter study. This study aims to measure the relationship between antimüllerian hormone serum level (AMH), as measured by a fully automated assay and the initial dose of Menopur® HP-hMG 600 IU/mL prescribed for infertile women undergoing their first IVF/ICSI cycle in the current practice.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Hormones
Menotropins
Criteria
Inclusion Criteria:

- Women aged between [18-42] years.

- Both ovaries present.

- Regular menstrual cycles presumed to be ovulatory.

- Primary or secondary infertility of any origin for more than 12 months.

- Patient with at least one result of antimüllerian hormone (AMH) measured by a fully
automated assay available before inclusion, and performed in the past 12 months before
inclusion.

- Candidates eligible to a first IVF/ICSI cycle and for whom Menopur® HP-hMG 600 IU/mL
has been prescribed.

- Having received oral and written information on the study, without any objections for
the use of his/her anonymized data, and having signed a written Informed Consent Form.

Exclusion Criteria:

- Major uterine or ovarian morphological abnormalities or past ovarian surgery.

- Endometriosis stage III/IV.

- Polycystic ovarian syndrome.

- Major endocrine or metabolic abnormalities without treatment.

- Patient included in an interventional study assessing treatment for infertility.